Epstein M A
Lancet. 1986 Jun 21;1(8495):1425-7. doi: 10.1016/s0140-6736(86)91565-5.
A vaccine derived from the high-molecular-weight glycoprotein (gp340) component of the Epstein-Barr (EB) virus membrane antigen conferred complete protection against a 100% lymphomagenic dose of EB virus in the cottontop tamarin, the animal of choice for experiments with EB virus. The membrane-antigen gene has already been cloned, and the development of a vaccine for use in man should now be possible. Such a vaccine could be tested first against infectious mononucleosis, because the effectiveness of vaccination would become evident in a relatively short time. Field trials against Burkitt's lymphoma and nasopharyngeal cancer could follow.
一种源自爱泼斯坦-巴尔（EB）病毒膜抗原高分子量糖蛋白（gp340）成分的疫苗，能为绢毛猴提供完全保护，使其免受100%致淋巴瘤剂量的EB病毒侵害。绢毛猴是进行EB病毒实验的首选动物。膜抗原基因已经被克隆，现在应该有可能开发出一种供人类使用的疫苗。这种疫苗可以首先针对传染性单核细胞增多症进行测试，因为疫苗接种的效果会在相对较短的时间内显现出来。接下来可以针对伯基特淋巴瘤和鼻咽癌进行现场试验。
